Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy

31 Jan 2021

Abstract excerpt

The four-component meningococcal serogroup B vaccine (4CMenB) contains antigens present in the majority of meningococci causing invasive meningococcal disease (IMD) and may potentially offer protection against strains belonging to non-B serogroups.This study aimed to evaluate the ability of 4CMenB-induced antibodies to kill, in a human serum bactericidal assay (hSBA), non-B meningococci belonging to the main...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Peptidase Inhibition and Analysis
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33522380
DOI: 10.1080/21645515.2020.1855951

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in ItalyPMID 33522380Read ↗

Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 Neisseria meningitidis isolates causing invasive meningococcal disease in Argentina in 2010-2014.Semantic proximity Read ↗

Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolatesSemantic proximity Read ↗

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern SpainSemantic proximity Read ↗

Meningococcal B vaccine antigen FHbp variants among disease-causing Neisseria meningitidis B isolates, Italy, 2014-2017.Semantic proximity Read ↗

Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines.Semantic proximity Read ↗

A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.Semantic proximity Read ↗

Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.Semantic proximity Read ↗

The Development of a Vaccine Against Meningococcus B Using Reverse VaccinologySemantic proximity Read ↗

Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years; Vaccine Efficiency PrognosisSemantic proximity Read ↗

Product review on the IMD serogroup B vaccine Bexsero®Semantic proximity Read ↗

Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine.Semantic proximity Read ↗

Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effectSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.